Perrigo Company plc Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Perrigo Company plc (PRGO) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of $205.30 million for the 12-month period ending 2014-06-28, per its 10-K filed 2014-08-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2014-08-14
- Perrigo Company plc income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2014 was $205.30M, a 53.54% decline from fiscal 2013.
- Perrigo Company plc income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2013 was $441.90M, a 12.44% increase from fiscal 2012.
- Perrigo Company plc income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2012 was $393.00M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|
| 2014-06-28 | $205.30M 10-K · filed 2014-08-14 |
| 2013-06-29 | $441.90M 10-K · filed 2014-08-14 |
| 2012-06-30 | $393.00M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |